UnitedHealth Group says the Justice Department’s antitrust challenge to its proposed $3.3 billion purchase of Amedisys is wrong on the merits and threatens to deprive consumers of benefits from ...

Amedisys, Inc. (NASDAQ:AMED – Free Report) – Research analysts at Leerink Partnrs cut their FY2024 earnings estimates for Amedisys in a note issued to investors on Wednesday, January 29th.

Amedisys has a 1-year low of $82.15 and a 1-year high of $98.95. The company has a market cap of $3.03 billion, a PE ratio of 36.71, a price-to-earnings-growth ratio of 1.82 and a beta of 0.73.

BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the ...

In a report released on January 29, Whit Mayo from Leerink Partners reiterated a Hold rating on Amedisys (AMED – Research Report), with a price target of $101.00. Whit Mayo has given his Hold ...